Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2024 16:00 ET | Source: Dyadic International, Inc.

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical...
March 13, 2024 16:05 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical...
March 07, 2024 16:05 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
June 21, 2023 08:33 ET | Source: Dyadic International, Inc.

Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity

JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
May 10, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic to Participate at Two Industry Events in May

JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
March 07, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 ...
August 10, 2022 16:00 ET | Source: Dyadic International, Inc.

Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments

Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
September 23, 2020 09:30 ET | Source: JRSIS Health Care Corp

JRSIS Health Care Corporation Spokesperson, Mary Xing, Discusses the Business Model and Markets for the Company in a New Audio Interview at SmallCapVoice.com

AUSTIN, Texas, Sept. 23, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with JRSIS Health Care Corp. (“the Company”) (OTCQX: JRSS), a...
August 26, 2019 08:17 ET | Source: PreCheck Health Services, Inc

PreCheck Health Services Signs Additional Binding Agreement to Acquire Companies to Strengthen Its Point-of-Care Medical Screening Capabilities

LD Technology manufactures and markets multiple products in the medical device screening sector, including the PC8BMedical Screening Inc. holds and owns all patents and proprietary technology of LD...
March 19, 2018 08:32 ET | Source: Cemtrex Inc.

Cemtrex Announces Partnership Program for its Augmented Reality WorkbenchXR tool Due to Overwhelming Interest

Farmingdale, NY, March 19, 2018 (GLOBE NEWSWIRE) -- Cemtrex Inc. (Nasdaq: CETX, CETXP, CETXW), a world leading technology and manufacturing company, today announced that it is launching a new Early...

Next Page keyboard_arrow_right